Equities analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will post sales of $1.10 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for AcelRx Pharmaceuticals’ earnings. The lowest sales estimate is $800,000.00 and the highest is $1.40 million. AcelRx Pharmaceuticals posted sales of $1.49 million during the same quarter last year, which suggests a negative year-over-year growth rate of 26.2%. The company is expected to announce its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year sales of $4.83 million for the current fiscal year, with estimates ranging from $1.00 million to $11.00 million. For the next fiscal year, analysts expect that the firm will post sales of $19.90 million per share, with estimates ranging from $11.00 million to $30.50 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.93 million.

A number of brokerages have recently commented on ACRX. ValuEngine raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of AcelRx Pharmaceuticals in a research note on Thursday, June 14th. LADENBURG THALM/SH SH began coverage on shares of AcelRx Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a research note on Thursday, August 9th. Finally, Oppenheimer reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $5.21.

Shares of ACRX stock opened at $3.05 on Friday. AcelRx Pharmaceuticals has a 52 week low of $1.55 and a 52 week high of $5.75. The company has a current ratio of 4.01, a quick ratio of 3.96 and a debt-to-equity ratio of -0.15. The firm has a market capitalization of $187.86 million, a PE ratio of -2.77 and a beta of 2.13.

In other AcelRx Pharmaceuticals news, insider Pamela P. Palmer bought 37,000 shares of the business’s stock in a transaction dated Monday, August 6th. The shares were acquired at an average price of $2.75 per share, with a total value of $101,750.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Vincent J. Angotti bought 10,000 shares of the business’s stock in a transaction dated Tuesday, August 7th. The stock was acquired at an average cost of $2.90 per share, for a total transaction of $29,000.00. The disclosure for this purchase can be found here. In the last three months, insiders bought 67,600 shares of company stock worth $193,192. Insiders own 25.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lincoln Capital Corp acquired a new stake in AcelRx Pharmaceuticals during the 2nd quarter valued at $116,000. GSA Capital Partners LLP acquired a new stake in AcelRx Pharmaceuticals during the 1st quarter valued at $113,000. Granite Investment Partners LLC acquired a new stake in AcelRx Pharmaceuticals during the 2nd quarter valued at $182,000. Northern Trust Corp grew its holdings in AcelRx Pharmaceuticals by 60.8% during the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares in the last quarter. Finally, FMR LLC grew its holdings in AcelRx Pharmaceuticals by 1,094.6% during the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 273,644 shares in the last quarter. 7.08% of the stock is owned by institutional investors and hedge funds.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Recommended Story: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.